Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.
Journal: Blood advances
Published: May 13, 2025
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 04, 2021
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013.
Journal: Journal of patient-reported outcomes
Published: February 24, 2020
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
Journal: Journal of clinical pharmacology
Published: August 28, 2019
Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 07, 2019
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 10, 2017
Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713.
Journal: Clinical colorectal cancer
Published: February 03, 2017
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Journal: JAMA
Published: December 29, 2016
Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 06, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026